ReviewDiabetes, obesity & metabolism2024
The clinical importance of measuring glycaemic variability: Utilising new metrics to optimise glycaemic control.
Review in Diabetes, obesity & metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Short-term glycemic variability and the risk of adverse ICU outcomes in critically ill patients: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Pooled it
- Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan-O-AP and LixiLan-L-CN.Diabetes, obesity & metabolism · 2026Trial
- Trial
- Trial
- Letter to the Editor: The Association Between Glycemic Variability and the Risk of Diabetic Retinopathy Progression: A Community-Based Retrospective Cohort Study.Journal of diabetes · 2026Article
- Biochemical and brain heterogeneity characterizes psychiatric and non-psychiatric illness.Nature communications · 2026Article
- Continuous glucose monitoring-based evaluation of percentage coefficient of variation (%CV) as a metric of intraday glycemic variability in South India.Scientific reports · 2026Article
- Glycemic outcomes with smart MDI system in type 1 diabetes: insights from a 12-Month retrospective study.Endocrine · 2026Observational
- Continuous glucose monitoring and microvascular complications in diabetes: Bridging glycemic metrics with clinical outcomes.Diabetes, obesity & metabolism · 2026Review
- The Impact of Glycaemic Variability on Vascular Dysfunction in Diabetes.Biomolecules · 2025Review
- Article
- Synergistic Association of Glycemic Variability and Severe Vitamin D Deficiency with Proliferative Diabetic Retinopathy.Nutrients · 2025Article
- Mobile application-based lifestyle intervention for improving glycemic control and body composition in manufacturing company employees in South Korea.Diabetology & metabolic syndrome · 2025Article
- Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist.Diabetes, obesity & metabolism · 2025Review
- Heterogeneity of continuous glucose monitoring features and their clinical associations in a type 2 diabetes population.Diabetes, obesity & metabolism · 2025Article
- Plasma C-Peptide Level and Continuous Glucose Monitoring-Derived Coefficient of Variation as a Predictable Risk Factor for Hypoglycemia in Koreans with Diabetes.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Comprehensive Assessment of Neuropathy and Metabolic Parameters in Type 1 Diabetic Patients with or Without Using Continuous Glucose Sensors.International journal of molecular sciences · 2025Article
- The clinical importance of measuring glycaemic variability: Utilising new metrics to optimise glycaemic control.Diabetes, obesity & metabolism · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the widespread use of continuous glucose monitoring (CGM), glycaemic variability (GV) is a glucose metric that has been gaining increasing attention. However, unlike other glucose metrics that are easily defined and have clear targets, GV has a large number of different measures given the complexity involved in assessment. While variabilities in HbA1c, fasting and postprandial glucose have been incorporated under the GV banner, short-term variability in glucose, within day and between days, is more in keeping with the correct definition of GV. This review is focused on short-term GV, as assessed by CGM data, although studies calculating GV from capillary glucose testing are also mentioned as appropriate. The different measures of GV are addressed, and their potential role in microvascular and macrovascular complications, as well as patient-related outcomes, discussed. It should be noted that the independent role of GV in vascular pathology is not always clear, given the inconsistent findings in different populations and the close association between GV and hypoglycaemia, itself an established risk factor for adverse outcomes. Therefore, this review attempts, where possible, to disentangle the contribution of GV to diabetes complications from other glycaemic parameters, particularly hypoglycaemia. Evidence to date strongly suggests an independent role for GV in vascular pathology but future large-scale outcome studies are required to fully understand the exact contribution of this metric to vascular complications. This can be followed by setting appropriate GV measures and targets in different diabetes subgroups, in order to optimise glycaemic management and limit the risk of complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.